Patent

Stanford Scientists First To Identify New Cellular Correlates of Protection Against Influenza for an Oral Flu Vaccine Developed by Vaxart

Retrieved on: 
Thursday, November 18, 2021
Shed, Cell Host & Microbe, Coronavirus, Refrigeration, HPV, Safety, Risk, Injury, Biomedical Advanced Research and Development Authority, Compliance, Stanford School, Clinical trial, SEC, CCR9, TLR3, Lancet, Department, Vaccine, BARDA, Vaccination, Immunology, Death, VXA, Microorganism, Stanford University, Research, GLOBE, Phase, Dis, Tablet, Patent, Development, RSV, FDA, Report, Quality control, CDC, Infection, Respiratory syncytial virus, NASDAQ, IIV, Norovirus, Pharmaceutical industry

Results of the Phase II study were the first to show that VXA-A1.1 offered greater protection against viral shedding than the injected IIV.

Key Points: 
  • Results of the Phase II study were the first to show that VXA-A1.1 offered greater protection against viral shedding than the injected IIV.
  • Random forest-based machine learning models were used to define high-dimensional cellular correlates between the immune profiling and viral shedding data.
  • Human influenza virus challenge identifies cellular correlates of protection for oral vaccination.
  • Efficacy, immunogenicity, and safety of an oral influenza vaccine: a placebo-controlled and active-controlled phase 2 human challenge study.

authID.ai to be Granted US Patent for Biometric Identity Authentication Routing Technology

Retrieved on: 
Thursday, November 18, 2021
Method, Patent, Sale, CEO, Face, Company, As a service, Theft, Database, GLOBE, Roger Hawkins (drummer), As, PAN, System, Online shopping, Cryptocurrency

The identity attributes are stored in a secure, encrypted database that can be accessed when called upon during identity authentication or verification transactions.

Key Points: 
  • The identity attributes are stored in a secure, encrypted database that can be accessed when called upon during identity authentication or verification transactions.
  • A transaction processor can then use the PAN to efficiently and securely facilitate a range of identity verification or authentication transactions.
  • authID.ai (Nasdaq: AUID), formerly Ipsidy, provides secure, mobile, biometric identity verification software products through an easy-to-integrate Identity as a Service (IDaaS) platform.
  • authIDs suite of self-service biometric identity proofing and authentication solutions aims to frictionlessly eliminate all usernames and passwords through a consent-based facial matching system.

U.S. Food and Drug Administration Approves Longeveron’s Lomecel-B for Rare Pediatric Disease Designation to Treat Life-Threatening Infant Heart Condition

Retrieved on: 
Thursday, November 18, 2021
Patient, HLHS, Congenital heart defect, Health status of Asian Americans, Security (finance), Advocate, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Safety, Review, Cell, Disorder, Ageing, MSC, Hypoplastic left heart syndrome, Trial of the century, Frailty, Company, Forward-looking statement, Microsoft, MD, Doctor of Philosophy, Weight gain, U.S. Securities and Exchange Commission, Intussusception (medical disorder), Program, Principal, Lung, Goal, Metabolic syndrome, Northwest Hospital & Medical Center, National Institute, NHLBI, GLOBE, Phase II, Adult, National Heart, Lung, and Blood Institute, Terminology, Patent, OH, Children's Hospital Los Angeles, Hospital, FDA, Colchester Hospital University NHS Foundation Trust, Bone marrow, RPD, Intention, NASDAQ, PRV, Food, Pharmaceutical industry

Lomecel-B, an investigational allogeneic, bone marrow-derived medicinal signaling cell (MSC) product, is currently being evaluated in a Phase 2 trial.

Key Points: 
  • Lomecel-B, an investigational allogeneic, bone marrow-derived medicinal signaling cell (MSC) product, is currently being evaluated in a Phase 2 trial.
  • We are encouraged by our Phase 1 clinical data, and the progress being made in the ongoing Phase 2 trial.
  • Lomecel-B represents a unique cell therapy approach that could potentially be administered at the same time as surgery in these critically impacted infants.
  • Longeveron recently reported clinical results from its safety-focused Phase I clinical study of Lomecel-B in HLHS patients.

Proactive news headlines including Pental Ltd, Lithium Power International, Orion Minerals and Aldoro Resources

Retrieved on: 
Thursday, November 18, 2021
Cloud, Lithium, Proactivity, Infinity, STM, VRC, KMC, OTCQX, PTL, CML, GLOBE, VMS, Observation, Science and technology in Asia, Lithology, FAK, Prieska, RGP, Cancer, Research, OTC, ATX, Diamond, CRC, Amaryllis, LEG, ASX, PAR, LRS, Ljig, LMG, Harbour View, Copper, Architecture, Douglas Mawson, JSE, Arunta, Patent, Soil, SHH, RTR, United States patent law, MZZ, ORN, ARN, Cloud Nine, Fibrosis, SPP, Quintana, Security (finance), Mining, Oil, Pharmaceutical industry, Rare-earth element, Uranium

Click here

Key Points: 
  • Click here
    Aldoro Resources Ltd (ASX:ARN) has collected 275 rock chip samples along the Fairway Corridor target at the Windimurra Igneous Complex in WA.
  • Click here
    Venture Minerals Limited (ASX:VMS, OTC:VTMLF) has returned high-grade zones of tin-tungsten mineralisation, including a 93-metre intersection, from its new drill program at Mount Lindsay Tin-Tungsten Project in northwest Tasmania.
  • Click here
    Volt Resources Ltd (ASX:VRC) has acquired three licence applications in Serbia Jadar North, Petlovaca and Ljig - that are considered prospective for lithium-borate mineralisation.
  • Click here
    Infinity Lithium Corporation Ltd (ASX:INF) has set up an incorporated subsidiary Infinity GreenTech Pty Ltd to commercialise a new low-carbon lithium hard rock processing technique.

Algenex and Biokit renew licensing agreement for insect-based production of human in vitro diagnostics

Retrieved on: 
Thursday, November 18, 2021
CEO, Industry, A-DNA, Antigen, IVD, COO, Parvoviridae, HSV, Health, Patent, Development, Vaccine

Biokit currently markets three commercial products that use antigens produced using Algenex technologies, including recombinant proteins for the detection of Herpes Simplex Virus (HSV) and Parvovirus.

Key Points: 
  • Biokit currently markets three commercial products that use antigens produced using Algenex technologies, including recombinant proteins for the detection of Herpes Simplex Virus (HSV) and Parvovirus.
  • Biokit is developing additional products, for which Algenex will receive royalties on net sales.
  • Claudia Jimnez, CEO of Algenex said We are pleased to continue our longstanding and successful relationship with Biokit, a world renowned IVD company.
  • We are pleased to renew this agreement and look forward to continuing to work with Algenex to deliver innovation and enhance patient care around the world.

Avenue Therapeutics Announces Exercise and Closing of Underwriter’s Over-Allotment Option

Retrieved on: 
Wednesday, November 17, 2021
Patient, Private Securities Litigation Reform Act, Security (finance), Sale, Pain, Securities Act of 1933, Fortress Biotech, Company, Forward-looking statement, Exercise, Form, Seventh Avenue, SEC filing, SEC, U.S. Securities and Exchange Commission, Telephone, COVID-19, S-3, Regulation, Prospectus, Securities Exchange Act of 1934, Research, Attention, GLOBE, Patent, FDA, Therapy, NASDAQ, Tramadol

Total gross proceeds to the Company from the offering, including the funds received from the prior closing and exercise of this option, are approximately $3 million, before deducting underwriting discounts, commissions, and other offering expenses payable by the Company.

Key Points: 
  • Total gross proceeds to the Company from the offering, including the funds received from the prior closing and exercise of this option, are approximately $3 million, before deducting underwriting discounts, commissions, and other offering expenses payable by the Company.
  • Aegis Capital Corp. acted as the sole book-running manager for the offering.
  • The offering was made pursuant to a registration statement on Form S-3 (File No.
  • 333-259850) previously filed with and declared effective by the Securities and Exchange Commission (the "SEC").

Tauriga Sciences Inc. Completes Production Run for 18,000 Dark Chocolate, 25mg CBD Infused Medallions

Retrieved on: 
Wednesday, November 17, 2021
Dark, Private Securities Litigation Reform Act, Patent, Security (finance), Hanukkah, Wappingers Falls, New York, Medication, Pharmaceutical Development and Technology, Forward-looking statement, Acquisition, Company, THC, Caffeine, DELTA, CBD, Arrival of a Train (Joinville Station), U.S. Securities and Exchange Commission, GLOBE, Master service agreement, AND, OTCQB, Patient, CBG, Candy, Risk management

NEW YORK, NY, Nov. 17, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a New York based diversified Life Sciences Company, today announced that it has completed its production run for 18,000 dark chocolate, CBD infused (25mg) Medallions.  These Medallions will be sold in Packs of 10 – for $39.99.  This product is Kosher Certified (Authority: Orthodox Union) and Halal Certified (Authority: Etimad).

Key Points: 
  • The Arrival of these Dark Chocolate Medallions comes just in time for Hanukkah!
  • The Company is gearing up for a strong Holiday Season 2021, to build upon what has already been a very good quarter (half way through).
  • Please visit our corporate website, for additional information, as well as inquiries, athttp://www.tauriga.com
    Complementary to the Companys retail business, is its ongoing Pharmaceutical Development initiative.
  • Provisional Patent Application (filed on March 17, 2020) into a U.S. Non-Provisional Patent Application.The Patent, filed with the U.S.P.T.O.

Sarepta Therapeutics Names Louise Rodino-Klapac, Ph.D., Head of Research and Development

Retrieved on: 
Wednesday, November 17, 2021
Patient, Patent, Security (finance), Investor Protection and Securities Reform Act of 2010, Muscular dystrophy, Review, Risk, Annual report, Company, Â, United States Patent and Trademark Office, SEC, U.S. Securities and Exchange Commission, COVID-19, Goal, Gene editing, R, Twitter, Research, GLOBE, SRPT, RNA, Instagram, DMD, Uncertainty, Duchenne muscular dystrophy, Therapy, LinkedIn, NASDAQ, Degenerative disease, Medical device

Dr. Rodino-Klapac inherits a strong research and development function.

Key Points: 
  • Dr. Rodino-Klapac inherits a strong research and development function.
  • Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short.
  • For a detailed description of risks and uncertainties Sarepta faces, you are encouraged to review the SEC filings made by Sarepta.
  • We routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com .

CoImmune, Inc. Announces Research Collaboration with Yeda Research and Development Company Ltd.

Retrieved on: 
Wednesday, November 17, 2021
Research, Mutagenesis, CAR, Interferon beta-1a, Cell, Technology, Physics, Brain, Yissum Research Development Company of the Hebrew University, Income, Canadian Aviation Regulations, SIN, Cancer, GVHD, CIK, Clinical trial, NK, Department, Program, Immunology, GLOBE, Patent, B cell, Artificial intelligence, RNA, Weizmann Institute of Science, Climate change, RNA transfection, Yeda, Immune system, Toxicity, Vaccine

We are very excited to join in this important collaboration with the research team at the Weizmann Institute of Science, said Mark DeBenedette, vice president of research and development at CoImmune.

Key Points: 
  • We are very excited to join in this important collaboration with the research team at the Weizmann Institute of Science, said Mark DeBenedette, vice president of research and development at CoImmune.
  • CoImmune is a privately held, clinical stage immuno-oncology company that will redefine cancer treatment using best-in-class cellular immunotherapies.
  • For more information visit www.coimmune.com
    Yeda Research and Development Company Ltd. is the commercial arm of the Weizmann Institute of Science.
  • Yeda currently manages approximately 500 unique patent families and has generated the highest income per researcher compared to any other academic technology transfer operation worldwide.

Frontier Medicines Announces the Appointment of Marguerite Hutchinson, J.D., as Chief Business Officer

Retrieved on: 
Wednesday, November 17, 2021
Patient, Harvard University, CEO, Industry, TGCT, Oncogene, University of San Diego School of Law, Cancer, Precision medicine, SAN, University, Program, UCSF, Intellectual property, Woman, Machine learning, Twitter, Mutation, GLOBE, Patent, UCSF Helen Diller Family Comprehensive Cancer Center, AbbVie, Frontier, Proteome, LinkedIn, Disease, Tenosynovial giant cell tumor, KRAS, Pharmaceutical industry

We are pleased to welcome Marguerite to our executive leadership team at Frontier, said Chris Varma, Ph.D., chairman, CEO, and co-founder of Frontier Medicines.

Key Points: 
  • We are pleased to welcome Marguerite to our executive leadership team at Frontier, said Chris Varma, Ph.D., chairman, CEO, and co-founder of Frontier Medicines.
  • Ms. Hutchinson was most recently the chief operating officer and general counsel of Plexxikon, overseeing all finance and operational aspects of the company, including business development, legal affairs, intellectual property and project management.
  • Frontier Medicines is a precision medicine company that has pioneered a powerful discovery and development platform designed to generate medicines against disease-causing proteins previously considered undruggable.
  • For more information on how Frontier is boldly advancing science to defeat disease, visit www.frontiermeds.com and follow us on LinkedIn and Twitter .